世界胃肠病学组织关于COVID-19合并肝病患者的诊疗指导
该指南由世界胃肠病学组织(WGO)制定,旨在阐明SARS-CoV-2对肝脏的影响。无症状转氨酶升高在COVID-19中常见,其发病机制可能涉及原发性肝损伤及“旁观者肝炎”、肌炎、毒性肝损伤、缺氧和既往肝病等多种因素。与轻型COVID-19相比,重型患者报告有更高的转氨酶升高、更低的白蛋白和血小板。合并既往肝病(尤其肝硬化)的COVID-19患者可出现慢加急性肝病/急性肝功能失代偿;代谢功能障碍相关脂肪性肝病(MAFLD)患者呼吸道疾病进展风险高于无MAFLD者。WGO推荐内镜及内镜逆行胰胆管造影仅用于急诊或严格必要情况(如高危静脉曲张或胆管炎),肝癌监测可推迟2至3个月,治疗启动可短期延迟并考虑非手术方法,肝移植应限制于高MELD评分、急性肝衰竭及符合米兰标准的肝细胞癌患者,供受者均应检测SARS-CoV-2,阳性供者应排除、移植推迟至感染恢复。
要点
- WGO推荐:内镜和ERCP仅用于急诊或严格必要情况,如高危静脉曲张或胆管炎。
- WGO推荐:肝细胞癌监测可推迟2至3个月。
- WGO推荐:肝移植应限制于高MELD评分、急性肝衰竭及符合米兰标准的肝细胞癌患者。
- WGO推荐:供者和受者均应检测SARS-CoV-2,阳性供者应排除,肝移植推迟至感染恢复。
- 重型COVID-19较轻型报告更高的转氨酶升高、更低的 albumin 和血小板;MAFLD患者呼吸道疾病进展风险高于无MAFLD者。
适用人群与场景
- COVID-19合并肝病患者,包括既往肝病尤其肝硬化、代谢功能障碍相关脂肪性肝病(MAFLD)、酒精相关肝病患者。
处置流程与药物剂量
- 内镜和ERCP应仅用于急诊病例或被认为严格必要的情况,如高危静脉曲张或胆管炎(WGO推荐)。
- 肝细胞癌监测可推迟2至3个月(WGO推荐)。
- 治疗启动可短期延迟,并应考虑非手术方法(WGO推荐)。
- 肝移植应限制于高MELD评分、急性肝衰竭及符合米兰标准的肝细胞癌患者(WGO推荐)。
- 供者和受者均应检测SARS-CoV-2;若发现阳性,供者应排除,肝移植推迟至感染恢复(WGO推荐)。
研究设计与关键结果
- 指南制定机构:世界胃肠病学组织(WGO);方法:未报告;证据分级体系:未报告。
证据类型、等级与局限
- 证据类型:指南;推荐强度:WGO推荐;局限:原文未报告局限性。
对床旁实践的改变
- WGO推荐内镜和ERCP仅用于急诊或严格必要情况(如高危静脉曲张或胆管炎),可减少非紧急操作。
- WGO推荐肝细胞癌监测可推迟2至3个月,可调整监测计划。
- WGO推荐肝移植应限制于高MELD评分、急性肝衰竭及符合米兰标准的肝细胞癌患者,可限制移植范围。
- WGO推荐供受者检测SARS-CoV-2,阳性供者排除、移植推迟至感染恢复,可改变移植前筛查流程。
指南或共识出处
- WGO Guidance for the Care of Patients With COVID-19 and Liver Disease(世界胃肠病学组织,WGO)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the least deadly but most infectious coronavirus strain transmitted from wild animals. It may affect many organ systems. Aim of the current guideline is to delineate the effects of SARS-CoV-2 on the liver. Asymptomatic aminotransferase elevations are common in coronavirus disease 2019 (COVID-19) disease. Its pathogenesis may be multifactorial. It may involve primary liver injury and indirect effects such as "bystander hepatitis," myositis, toxic liver injury, hypoxia, and preexisting liver disease. Higher aminotransferase elevations, lower albumin, and platelets have been reported in severe compared with mild COVID-19. Despite the dominance of respiratory disease, acute on chronic liver disease/acute hepatic decompensation have been reported in patients with COVID-19 and preexisting liver disease, in particular cirrhosis. Metabolic dysfunction-associated fatty liver disease (MAFLD) has a higher risk of respiratory disease progression than those without MAFLD. Alcohol-associated liver disease may be severely affected by COVID-19-such patients frequently have comorbidities including metabolic syndrome and smoking-induced chronic lung disease. World Gastroenterology Organization (WGO) recommends that interventional procedures such as endoscopy and endoscopic retrograde cholangiopancreatography should be performed in emergency cases or when they are considered strictly necessary such as high risk varices or cholangitis. Hepatocellular cancer surveillance may be postponed by 2 to 3 months. A short delay in treatment initiation and non-surgical approaches should be considered. Liver transplantation should be restricted to patients with high MELD scores, acute liver failure and hepatocellular cancer within Milan criteria. Donors and recipients should be tested for SARS-CoV-2 and if found positive donors should be excluded and liver transplantation postponed until recovery from infection.
参考来源
- Hamid S, Alvares da Silva MR, Burak KW, et al. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021. PMID: 33230011. doi:10.1097/MCG.0000000000001459
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。